New York, NY—December 11, 2025, Immunovant, Inc., a clinical-stage immunology company, dedicated to enabling normal lives for people with autoimmune diseases, has designated Lange Neurology PC, as a trial site for its Phase III study of IMVT-1402. The study aims to assess the efficacy and safety of IMVT-1402 in adult patients with mild to severe Myasthenia Gravis (MG).

“We are very excited to be part of the IMVT-1402 trial to determine if IMVT-1402 renders equivalent or better control of CIDP than IVIG or other agents,” Dr. Lange said. “Since IMVT is administered subcutaneously, a successful trial will give patients the ability to be more independent while maintaining or improving control of their CIDP.”